about
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.Precision oncology: neither a silver bullet nor a dream.Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformationsPonatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation
P2860
Q41348012-49E22D6D-5D7B-43FE-8FFA-04D840CC754CQ45790127-C8DDD4EE-CD81-4A85-9DBA-30B21AC90ECCQ47123875-63857A19-19B7-4403-A5BA-D54D224E517CQ47139100-DFA78BD7-2C35-40B7-A750-79387B114C9CQ47737073-E7BF5EBB-B598-476D-B8E4-0DD2DDCF9F13Q58699724-FEF2BBA2-13FB-4400-BC29-BE853EFF5993Q58761411-8C3251E6-36EF-46D5-B8E0-5B20BADBF698
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Ponatinib in the therapy of chronic myeloid leukemia.
@en
type
label
Ponatinib in the therapy of chronic myeloid leukemia.
@en
prefLabel
Ponatinib in the therapy of chronic myeloid leukemia.
@en
P2093
P2860
P1476
Ponatinib in the therapy of chronic myeloid leukemia.
@en
P2093
Hassan Sibai
Jeffrey H Lipton
Marc Poch Martell
Uday Deotare
P2860
P304
P356
10.1080/17474086.2016.1232163
P577
2016-09-02T00:00:00Z